Serum dopamine‐β‐hydroxylase levels in Down's syndrome

Mary Coleman; Ma Cda Campbell; Lewis S. Freedman; Mark Roffman; Richard P. Ebstein; Menek Goldstein

doi:10.1111/j.1399-0004.1974.tb01699.x

Serum dopamine‐β‐hydroxylase levels in Down's syndrome

Mary Coleman
, Ma Cda Campbell
, Lewis S. Freedman
, Mark Roffman
, Richard P. Ebstein
, Menek Goldstein^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Serum dopamine‐β‐hydroxylase (DBH) and serum immunoreactive (IR) DBH levels were measured in patients with Down's syndrome. Serum DBH activity was markedly reduced in Down's syndrome patients as compared with age matched, normal controls or non‐mongoloid, disturbed children. Serum IR‐DBH levels were also markedly reduced in Down's syndrome. The possible factors responsible for the observed reduction in serum DBH levels (active and inactive enzyme levels) in Down's syndrome were investigated.

Original language	English
Pages (from-to)	312-315
Number of pages	4
Journal	Clinical Genetics
Volume	5
Issue number	4
DOIs	https://doi.org/10.1111/j.1399-0004.1974.tb01699.x
State	Published - Apr 1974
Externally published	Yes

Access to Document

10.1111/j.1399-0004.1974.tb01699.x

Cite this

@article{d1b7e8d41a744ceba7e73a71c02c7e02,

title = "Serum dopamine‐β‐hydroxylase levels in Down's syndrome",

abstract = "Serum dopamine‐β‐hydroxylase (DBH) and serum immunoreactive (IR) DBH levels were measured in patients with Down's syndrome. Serum DBH activity was markedly reduced in Down's syndrome patients as compared with age matched, normal controls or non‐mongoloid, disturbed children. Serum IR‐DBH levels were also markedly reduced in Down's syndrome. The possible factors responsible for the observed reduction in serum DBH levels (active and inactive enzyme levels) in Down's syndrome were investigated.",

author = "Mary Coleman and Campbell, \{Ma Cda\} and Freedman, \{Lewis S.\} and Mark Roffman and Ebstein, \{Richard P.\} and Menek Goldstein",

year = "1974",

month = apr,

doi = "10.1111/j.1399-0004.1974.tb01699.x",

language = "אנגלית",

volume = "5",

pages = "312--315",

journal = "Clinical Genetics",

issn = "0009-9163",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - Serum dopamine‐β‐hydroxylase levels in Down's syndrome

AU - Coleman, Mary

AU - Campbell, Ma Cda

AU - Freedman, Lewis S.

AU - Roffman, Mark

AU - Ebstein, Richard P.

AU - Goldstein, Menek

PY - 1974/4

Y1 - 1974/4

N2 - Serum dopamine‐β‐hydroxylase (DBH) and serum immunoreactive (IR) DBH levels were measured in patients with Down's syndrome. Serum DBH activity was markedly reduced in Down's syndrome patients as compared with age matched, normal controls or non‐mongoloid, disturbed children. Serum IR‐DBH levels were also markedly reduced in Down's syndrome. The possible factors responsible for the observed reduction in serum DBH levels (active and inactive enzyme levels) in Down's syndrome were investigated.

AB - Serum dopamine‐β‐hydroxylase (DBH) and serum immunoreactive (IR) DBH levels were measured in patients with Down's syndrome. Serum DBH activity was markedly reduced in Down's syndrome patients as compared with age matched, normal controls or non‐mongoloid, disturbed children. Serum IR‐DBH levels were also markedly reduced in Down's syndrome. The possible factors responsible for the observed reduction in serum DBH levels (active and inactive enzyme levels) in Down's syndrome were investigated.

UR - https://www.scopus.com/pages/publications/0016198101

U2 - 10.1111/j.1399-0004.1974.tb01699.x

DO - 10.1111/j.1399-0004.1974.tb01699.x

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 4277651

AN - SCOPUS:0016198101

SN - 0009-9163

VL - 5

SP - 312

EP - 315

JO - Clinical Genetics

JF - Clinical Genetics

IS - 4

ER -

Serum dopamine‐β‐hydroxylase levels in Down's syndrome

Abstract

Access to Document

Other files and links

Fingerprint

Cite this